In our comparison series on weight loss medications, we compare different treatment options and explain how they differ from a medical perspective. This article focuses on Wegovy vs. Mounjaro: two modern medications for medical weight management that are frequently compared with each other.
Both medications are classically injected once weekly and can significantly influence hunger, satiety and body weight. However, they differ substantially: Wegovy contains semaglutide and acts as a GLP-1 receptor agonist. Mounjaro contains tirzepatide and acts on both GIP and GLP-1 receptors.
The question “Wegovy or Mounjaro?” therefore cannot be answered in general terms. In a direct comparison study, Mounjaro led to greater average weight loss than semaglutide. However, suitability, pre-existing conditions, tolerability, side effects, treatment goals and medical supervision remain decisive.
Table of Contents
- Wegovy vs. Mounjaro: Quick Comparison
- The Most Important Difference: Semaglutide vs. Tirzepatide
- What Is Wegovy?
- What Is Mounjaro?
- How Do Wegovy and Mounjaro Work?
- Which Medication Leads to More Weight Loss?
- Use and Dosage in Everyday Life
- Side Effects and Safety
- Update: What Does the Wegovy Pill Mean?
- Wegovy or Mounjaro: Which Is Suitable for Whom?
- More Comparisons in Our Series
- Medically Supervised Weight Loss at The Body Clinic
- Conclusion
- Frequently Asked Questions
Wegovy vs. Mounjaro: Quick Comparison
Wegovy and Mounjaro are both modern medications for medical weight management. They are often referred to as “weight loss injections”, but they differ in their active ingredient and mechanism of action.
| Aspect | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Medication class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Main goal | Medical weight management in suitable patients. | Medical weight management and treatment of type 2 diabetes, depending on the indication. |
| Use | Classically once weekly as a subcutaneous injection. | Once weekly as a subcutaneous injection. |
| Mechanism of action | Mimics GLP-1 effects and influences hunger, satiety and blood glucose regulation. | Activates GIP and GLP-1 signaling pathways and influences appetite, satiety and metabolism. |
| Weight loss in studies | Significant weight loss; in EMA data, around 15 percent after 68 weeks in a key study. | Often greater weight loss in studies; in SURMOUNT-5, greater than with semaglutide 2.4 mg. |
| Important | Not every person is suitable; medical assessment is required. | Not automatically “better” for every person; suitability and tolerability are decisive. |
The Most Important Difference: Semaglutide vs. Tirzepatide
The central difference between Wegovy and Mounjaro lies in the active ingredient. Wegovy contains semaglutide, while Mounjaro contains tirzepatide.
Semaglutide is a GLP-1 receptor agonist. It mimics the effect of the body’s own hormone GLP-1. Tirzepatide additionally acts on a second receptor: it activates both GIP and GLP-1 receptors. This is why tirzepatide is often described as a dual receptor agonist.
This does not mean that Mounjaro is automatically the better choice for everyone. It does mean, however, that Mounjaro has a different mechanism of action than Wegovy. This difference can play a role in effect, weight loss, tolerability and the individual treatment decision.
What Is Wegovy?
Wegovy is a prescription medication containing the active ingredient semaglutide. It is used for weight management in suitable patients. Treatment is used in addition to a reduced-calorie diet and increased physical activity.
Wegovy may be suitable for adults with obesity or overweight with at least one weight-related comorbidity. These may include type 2 diabetes, high blood pressure, abnormal blood lipid levels, sleep apnea or cardiovascular risks.
Wegovy is mainly known as a weekly injection. In addition, an oral Wegovy formulation was recommended by the EMA for approval extension in 2026. You can find more information on our page about the Wegovy pill.
What Is Mounjaro?
Mounjaro is a prescription medication containing the active ingredient tirzepatide. Tirzepatide acts on GIP and GLP-1 receptors and can therefore influence appetite regulation, satiety, blood glucose metabolism and body weight.
Mounjaro is used in adults with type 2 diabetes and is also relevant for weight management in adults with obesity or overweight with weight-related comorbidities. Here too, treatment is not used in isolation, but together with nutrition, physical activity and medical supervision.
Mounjaro is not a lifestyle product, but a medication for medically justified treatment situations. Whether it is suitable should be assessed individually.
How Do Wegovy and Mounjaro Work?
Wegovy and Mounjaro both act on hormonal signaling pathways that are relevant for hunger, satiety, energy intake and metabolism. The difference lies in which receptors are targeted.
| Effect Aspect | Wegovy | Mounjaro |
|---|---|---|
| GLP-1 effect | Yes, semaglutide acts as a GLP-1 receptor agonist. | Yes, tirzepatide also activates GLP-1 receptors. |
| GIP effect | No, Wegovy does not act as a dual GIP/GLP-1 agonist. | Yes, tirzepatide additionally activates GIP receptors. |
| Appetite and satiety | Hunger can decrease, and satiety can occur earlier. | Hunger and food cravings can also decrease significantly. |
| Blood glucose | Semaglutide supports glucose-dependent insulin release. | Tirzepatide can also significantly influence blood glucose control. |
| Gastric emptying | May be slowed. | May also be slowed. |
Both medications can therefore help patients feel less hungry, become full sooner and eat smaller portions. This can create a calorie deficit, which leads to weight loss.
Which Medication Leads to More Weight Loss?
The question of greater weight loss is one of the main reasons why Wegovy and Mounjaro are compared. The evidence suggests that tirzepatide can achieve greater average weight reductions than semaglutide 2.4 mg.
The direct SURMOUNT-5 study is particularly relevant. It compared tirzepatide with semaglutide 2.4 mg in adults with obesity or overweight without diabetes. After 72 weeks, the average percentage weight loss was greater with tirzepatide than with semaglutide.
| Study Aspect | Tirzepatide | Semaglutide 2.4 mg |
|---|---|---|
| Direct comparison | SURMOUNT-5 directly investigated tirzepatide against semaglutide. | Semaglutide 2.4 mg was the comparator treatment. |
| Duration | 72 weeks. | 72 weeks. |
| Average weight change | About minus 20.2 percent. | About minus 13.7 percent. |
| Waist circumference | Greater reduction than with semaglutide. | Also showed a relevant reduction, but smaller in direct comparison. |
These data are important, but they do not replace an individual treatment decision. Study results show averages. In everyday life, tolerability, pre-existing conditions, side effects, eating behavior, accompanying therapy, costs, availability and personal goals can be just as important.
In addition, weight loss is not the only goal. Safe treatment should also take muscle mass, nutrient intake, eating structure and long-term weight stabilization into account. You can find more on this in the article Preserving Muscle Mass Despite a Calorie Deficit.
Use and Dosage in Everyday Life
Wegovy and Mounjaro are classically used once weekly as subcutaneous injections. This means the medication is injected under the skin, for example into the abdomen, thigh or upper arm.
With both medications, the dose is usually increased gradually. This slow dose escalation is intended to improve tolerability, because side effects can occur especially at the beginning of treatment or after dose increases.
| Everyday Question | Wegovy | Mounjaro |
|---|---|---|
| How often? | Once weekly. | Once weekly. |
| How? | Subcutaneous injection. | Subcutaneous injection. |
| Dose escalation? | Gradual increase according to a medical schedule. | Gradual increase according to a medical schedule. |
| Can the dose be adjusted independently? | No, not without medical advice. | No, not without medical advice. |
| Tablet option? | An oral Wegovy formulation was recommended by the EMA for approval extension in 2026. | Mounjaro is currently mainly known as an injection. |
Important: use should not be changed independently. Anyone who has side effects, can barely eat, vomits repeatedly or feels unsure should have the therapy medically reviewed.
Side Effects and Safety
Wegovy and Mounjaro can cause similar side effects because both influence hormonal satiety and digestive signals. Gastrointestinal symptoms are particularly common.
These include nausea, diarrhea, constipation, vomiting, abdominal pain or fullness. Such symptoms often occur at the beginning of treatment or after dose increases and are often mild to moderate. Nevertheless, persistent or severe symptoms should be medically assessed.
| Topic | Possible Meaning | What Matters |
|---|---|---|
| Nausea | Satiety and gastric emptying change. | Small portions, eating slowly, reducing very fatty meals. |
| Diarrhea or constipation | Digestion, fluid intake, fiber and food volume change. | Drink enough, increase fiber slowly and monitor symptoms. |
| Eating too little | Reduced hunger can lead to skipped meals. | Plan protein, energy and nutrients consciously. |
| Muscle loss | With significant weight loss, lean mass can also be lost. | Consider protein, strength training and follow-up. |
| Independent combination | Using both medications together or switching without supervision can increase risks. | No self-medication, no independent switching, no combination without medical supervision. |
Practical guidance on nutrition during therapy can be found in our article on the Do’s and Don’ts of nutrition during medication-assisted weight loss. We explain why eating too little during GLP-1 therapy can become problematic in the article What if I Eat Too Little During Therapy?.
Update: What Does the Wegovy Pill Mean?
A current difference concerns the dosage form. Wegovy has so far mainly been known as a weekly injection. In May 2026, however, the EMA recommended an approval extension for an oral Wegovy formulation.
This Wegovy pill would be an oral alternative to the injection for adults with obesity or overweight with at least one weight-related comorbidity. It would still be prescription-only and would need to be taken according to medical instructions.
For the comparison with Mounjaro, this means: Wegovy could also become relevant as a pill in the future, while Mounjaro is still mainly classified as a weekly injection. Whether and when a tablet form actually becomes suitable in everyday life depends on approval, availability, price, reimbursement and individual suitability.
You can find more information on our page about the Wegovy pill and in our article on the future of weight loss medications.
Wegovy or Mounjaro: Which Is Suitable for Whom?
The question “Wegovy or Mounjaro?” should not be answered based solely on average weight loss. Mounjaro can be more effective in studies, but the individually suitable medication depends on many factors.
| Situation | Possible Interpretation | Important |
|---|---|---|
| Greater weight reduction is the main priority | Mounjaro may be particularly relevant based on study data. | Individual suitability, tolerability and risks must still be assessed. |
| Semaglutide therapy is preferred or already established | Wegovy may be a suitable option. | Treatment goal, comorbidities and previous experience should be considered. |
| Fear of injections or wish for an oral option | The Wegovy pill could become relevant in the future. | Availability, administration requirements and suitability should be medically assessed. |
| Side effects or very low food intake | Treatment should be reviewed and adjusted if necessary. | Do not pause, switch or adjust the dose independently. |
| Type 2 diabetes or other conditions | Indication and comorbidities influence the decision. | Medical assessment is decisive. |
It is also important that Wegovy and Mounjaro should not be used together or exchanged independently. Any switch should only be planned by a doctor.
More Comparisons in Our Series
If you would like to compare different weight loss medications, these articles may also be helpful:
- Wegovy vs. Ozempic: The Main Differences
- Wegovy vs. Saxenda: The Main Differences
- Mounjaro vs. Ozempic: The Main Differences
- Mounjaro vs. Saxenda: The Main Differences
- Ozempic vs. Saxenda: The Main Differences
- Semaglutide Medications Compared
Medically Supervised Weight Loss at The Body Clinic
At The Body Clinic, medically supervised weight loss is the focus. This means that a medication is not viewed in isolation, but in connection with health status, treatment goal, nutrition, physical activity, side effects and long-term stabilization.
If Wegovy, Mounjaro or other options may be suitable, we assess which treatment makes medical sense. You can find an overview of possible treatment options on our page about medication for weight loss.
Especially with highly effective medications, guidance remains important. We explain why nutrition continues to play a central role despite GLP-1 medications in the article Why GLP-1 Needs Guidance.
If you would like to check whether medical weight loss may generally be suitable for you, you can check your eligibility for medical weight loss. Information on potential costs can be found on our page about the costs of medical weight loss.
Conclusion
Wegovy and Mounjaro are both relevant medications for medical weight management, but they differ significantly. Wegovy contains semaglutide and acts as a GLP-1 receptor agonist. Mounjaro contains tirzepatide and acts on GIP and GLP-1 receptors.
In direct study data, tirzepatide showed greater average weight loss than semaglutide 2.4 mg. This makes Mounjaro a very important treatment option, but it does not mean that it is automatically the best choice for every person.
Medical suitability, pre-existing conditions, tolerability, side effects, everyday life, nutrition, physical activity and long-term support are decisive. Anyone weighing Wegovy against Mounjaro should therefore not make the decision based on percentages alone, but should have it assessed medically.
Frequently Asked Questions
What Is the Difference Between Wegovy and Mounjaro?
Wegovy contains semaglutide and acts as a GLP-1 receptor agonist. Mounjaro contains tirzepatide and acts on GIP and GLP-1 receptors. Both can be used for medical weight management, but they differ in their mechanism of action.
Is Mounjaro Stronger Than Wegovy?
In direct study data, tirzepatide, the active ingredient in Mounjaro, led to greater average weight loss than semaglutide 2.4 mg. However, the individual effect can vary.
What Is Better: Wegovy or Mounjaro?
This cannot be answered in general terms. Mounjaro may be more effective on average, but Wegovy may be relevant depending on the medical situation, tolerability, experience, availability or interest in a future tablet option. The decision should be made medically.
Can You Switch From Wegovy to Mounjaro?
A switch should never be made independently. If a switch appears medically appropriate, it must be planned by a doctor so that dosage, tolerability, indication and possible risks are considered.
Can Wegovy and Mounjaro Be Used Together?
No, independent combination is not intended and may increase risks. Wegovy and Mounjaro should not be used at the same time unless a doctor makes a specific medical decision.
Do Wegovy and Mounjaro Have Similar Side Effects?
Yes, many possible side effects are similar, especially gastrointestinal symptoms such as nausea, diarrhea, constipation, vomiting or abdominal pain. Severity and frequency can vary individually.
Are Wegovy or Mounjaro Available as Tablets?
Wegovy is mainly known as an injection. In May 2026, the EMA recommended an approval extension for a Wegovy pill. Mounjaro is currently mainly known as a weekly injection.
Which Medication Is Better for Me?
That depends on BMI, comorbidities, previous treatments, tolerability, side effects, everyday routine, costs, availability and treatment goal. A medical eligibility assessment is therefore decisive.
Sources
- Wegovy EPAR, European Medicines Agency
- Mounjaro EPAR, European Medicines Agency
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, New England Journal of Medicine
- American College of Cardiology: SURMOUNT-5 summary
- EMA: First oral GLP-1 treatment for weight management
- Wegovy EPAR Product Information, European Medicines Agency
- Mounjaro EPAR Product Information, European Medicines Agency